New hope for hard-to-treat ovarian cancer: targeted drug shows promise in early trial
NCT ID NCT06028932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called sacituzumab govitecan in 20 people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The drug works like a guided missile, delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear. Participants must have measurable disease and provide a tumor sample for testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510, United States